1. Home
  2. FRD vs AGEN Comparison

FRD vs AGEN Comparison

Compare FRD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$19.13

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$4.63

Market Cap

124.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
AGEN
Founded
1965
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
124.4M
IPO Year
1995
1999

Fundamental Metrics

Financial Performance
Metric
FRD
AGEN
Price
$19.13
$4.63
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
25.7K
909.4K
Earning Date
02-09-2026
05-11-2026
Dividend Yield
0.84%
N/A
EPS Growth
N/A
100.00
EPS
1.46
N/A
Revenue
$121,157,278.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$13.09
$8.89
Revenue Growth
55.82
89.95
52 Week Low
$14.01
$1.96
52 Week High
$24.37
$7.34

Technical Indicators

Market Signals
Indicator
FRD
AGEN
Relative Strength Index (RSI) 60.34 64.33
Support Level $18.15 $3.92
Resistance Level $19.52 $5.20
Average True Range (ATR) 0.69 0.37
MACD 0.21 0.11
Stochastic Oscillator 86.51 75.74

Price Performance

Historical Comparison
FRD
AGEN

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: